暂无简介。

入排标准

•- Subject participating to Study 25878 currently treated or having been treated with efalizumab, with the last dose received within 6 weeks before inclusion in this trial.
•- Subject developing during the study 25878 either:
•* a newly diagnosed autoimmune disease (suspected or confirmed)
•* a severe thrombocytopenia defined as grade III or IV according to NCI-CTCAE cirteria
•- subject is willing and able to participate in the trial and has provided signed, informed consent.;For subjects of control group:
•- subject is either currently treated with efalizumab or not (i.e. last dose of efalizumab received more than 6 weeks before study entry)

•- Participation to any interventional clinical study (inclusion in other registry/observational study is possible).
•- Administration of specific treatment for the current thrombocytopenia before inclusion in the study.

Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with Raptiva (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST). - CLEAREST-TRAI

试验速览